TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
TuHURA Biosciences (Nasdaq: HURA), a Phase 3 registration-stage immune-oncology company, announced its participation in the 2024 Maxim Healthcare Virtual Summit. Dr. James Bianco, President and CEO of TuHURA, was part of the Precision and Immune Oncology panel. The company focuses on developing novel technologies to overcome resistance to cancer immunotherapy. A webcast replay of the panel presentation is available for M-Vest members.
TuHURA Biosciences (Nasdaq: HURA), un'azienda di immuno-oncologia in fase di registrazione di Fase 3, ha annunciato la sua partecipazione al Virtual Summit di Maxim Healthcare del 2024. Il Dr. James Bianco, Presidente e CEO di TuHURA, ha preso parte al panel sulla Precisione e Immuno-Oncologia. L'azienda si concentra sullo sviluppo di tecnologie innovative per superare la resistenza all'immunoterapia contro il cancro. Una registrazione della presentazione del panel è disponibile per i membri di M-Vest.
TuHURA Biosciences (Nasdaq: HURA), una empresa de oncología inmunológica en fase de registro de Fase 3, anunció su participación en la Cumbre Virtual de Maxim Healthcare 2024. El Dr. James Bianco, Presidente y CEO de TuHURA, formó parte del panel de Oncología Inmunológica y de Precisión. La empresa se enfoca en el desarrollo de tecnologías novedosas para superar la resistencia a la inmunoterapia contra el cáncer. Una retransmisión de la presentación del panel está disponible para los miembros de M-Vest.
TuHURA 바이오사이언스(TuHURA Biosciences, Nasdaq: HURA)는 2024 맥심 헬스케어 가상 정상 회담에 참여한다고 발표했습니다. TuHURA의 사장 겸 CEO인 제임스 비앙코 박사는 정밀 면역 항암 패널의 일원으로 초대받았습니다. 이 회사는 암 면역 요법에 대한 저항을 극복하기 위한 혁신적인 기술 개발에 집중하고 있습니다. 패널 발표의 웹캐스트 재방송이 M-Vest 회원들을 위해 제공됩니다.
TuHURA Biosciences (Nasdaq: HURA), une entreprise d’immuno-oncologie en phase d’enregistrement de Phase 3, a annoncé sa participation au Sommet Virtuel 2024 de Maxim Healthcare. Dr. James Bianco, Président et CEO de TuHURA, faisait partie du panel sur la Précision et l’Immuno-Oncologie. L’entreprise se concentre sur le développement de technologies novatrices pour surmonter la résistance à l’immunothérapie contre le cancer. Un enregistrement de la présentation du panel est disponible pour les membres de M-Vest.
TuHURA Biosciences (Nasdaq: HURA), ein Unternehmen im Bereich Immunonkologie in der Registrierungsphase der Phase 3, hat seine Teilnahme am Virtual Summit 2024 von Maxim Healthcare angekündigt. Dr. James Bianco, Präsident und CEO von TuHURA, war Teil des Panels für Präzisions- und Immunonkologie. Das Unternehmen konzentriert sich auf die Entwicklung neuartiger Technologien zur Überwindung der Resistenz gegenüber der Krebsimmuntherapie. Eine Wiederholung der Panel-Präsentation ist für M-Vest-Mitglieder verfügbar.
- TuHURA's participation in a high-profile healthcare summit may increase visibility and investor interest.
- None.
TAMPA, FL / ACCESSWIRE / October 23, 2024 / TuHURA Biosciences, Inc. (Nasdaq:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that TuHURA recently participated at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC.
As part of the event, Dr. James Bianco, President and Chief Executive Officer of TuHURA participated in the Precision and Immune Oncology panel. To access the webcast replay, sign up to become anM-Vest member.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.
Investor Contact:
Jenene Thomas
JTC Team, LLC
908.824.0775
tuhura@jtcir.com
SOURCE: TuHURA Biosciences, Inc.
View the original press release on accesswire.com
FAQ
What event did TuHURA Biosciences participate in?
Who represented TuHURA at the 2024 Maxim Healthcare Virtual Summit?
What was the focus of TuHURA Biosciences' panel at the summit?
How can one access the webcast replay of TuHURA's panel presentation?
